A phase 2 biomarker-driven study using epidermal growth factor receptor 1 FGFR1 gene copy number by silver in-situ hybridization (SISH) and messenger RNA expression by in-situ hybridization (ISH) in lung cancer patients treated with ponatinib was conducted. FGFR1 ISH and SISH positivity may be associated with a distinct phenotype. Ponatinib's poor tolerance limited the number of patients treated on study. Introduction: Preclinically, high epidermal growth factor receptor 1 (FGFR1) messenger RNA (FGFR1-MRNA) and FGFR1 amplification (FGFR1-AMP) predicted sensitivity to fibroblast growth factor receptor inhibitors in nonesmallcell lung cancer and small-cell lung cancer cell lines. KRAS mutations did not preclude sensitivity. Patients and Methods: Metastatic EGFR-and ALK-negative lung cancers were screened for FGFR1-MRNA by in-situ hybridization (ISH) and FGFR1-AMP by silver in-situ hybridization (SISH). Patients with positive findings were offered ponatinib, a multiekinase inhibitor of FGFR1-4. Differences in overall survival (OS) between cohorts were assessed by the log-rank test. Association of FGFR1 positivity with clinicopathologic features were assessed by Fisher exact test and KruskalWallis rank sum test. Results: A total of 171 cases were prescreened: 9 (7.3%) of 123 SISH þ ; 53 (42.1%) of 126 ISH þ ; and 6 cases concordantly positive for SISH and ISH. SISH þ cases had fewer coincident KRAS mutations (P ¼ .03) than SISH À cases, and ISH þ cases had worse OS (P ¼ .020) than ISH À cases. Data distributions suggested a distinct higher positivity cut point for FGFR1 ISH (! 20%), occurring in 29 (23%) of 126 cases, was associated with small-cell lung cancer histology (P ¼ .022), soft tissue metastases (P ¼ .050) and shorter OS (P ¼ .031). Four patients received ponatinib on study: All ISH þ by the initial cut point, 2 of 4 by higher cut point, 1 of 4 SISH þ . Tolerability was poor. The best response for the 2 higher ISH cases was stable disease and progressive disease for the 2 lower ISH cases. Conclusion: Elevated FGFR1-MRNA is more common than FGFR1-AMP and associated with worse OS. Higher FGFR1 mRNA expression may be associated with a specific phenotype and is worthy of further exploration. Ponatinib's poor tolerance suggests further fibroblast growth factor receptor exploration in ISH þ cases should utilize more selective FGFR1 inhibitors.
Introduction
Over the last decade, the paradigm of advanced nonesmall-cell lung cancer (NSCLC) management has been revolutionized by the advent of identifiable, targetable oncogenic drivers, such as epidermal growth factor receptor (EGFR) activating mutations, anaplastic lymphoma kinase (ALK ), and ROS1 gene rearrangement. Treatment of these molecular subsets of lung cancer using specific tyrosine kinase inhibitors has led to high objective response rates (ORRs) of 40% to 70%, which are often durable, and generally the tyrosine kinase inhibitors have had better tolerability compared to cytotoxic drugs. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, success in discovering novel oncogene drivers in lung cancer has been limited to the adenocarcinoma histologic subtype of NSCLC. The discovery and exploitation of targetable oncogenic drivers in squamous NSCLC (SQLC) and in small-cell lung cancer (SCLC) continues to be explored. The fibroblast growth factor receptor (FGFR) comprises a family of 4 transmembrane receptor tyrosine kinases (FGFR1-4) that regulate cellular proliferation, differentiation, and survival. Binding of a large range of different mitogenic and hormonal ligands to the relevant receptor leads to FGFR dimerization and downstream signaling via the PI3K, RAS/RAF/MAPK, and protein kinase C pathways. 10, 11 A comprehensive effort to molecularly profile 178 SQLC identified alterations in FGFR1-4 in 27% of cases, with FGFR1 gene amplification being the most common event. 12 Other sequencing efforts of SQLC suggest a similarly high frequency of FGFR1 amplification (FGFR1-AMP), and preclinical studies demonstrated response to FGFR1 inhibition in FGFR1-amplified SQLC in vitro and in vivo. [13] [14] [15] FGFR1-AMP has also been reported in SCLC in a small subset, together with possible dependence on the FGFR signaling pathway. [16] [17] [18] Given the relatively high frequency of FGFR1-AMP, fluorescent in-situ hybridization (FISH) for FGFR1 was used to select SQLC patients for treatment with different FGFR inhibitors in several clinical trials. Unfortunately, ORRs following this approach have been low (8%-11.5%), with a disease control rate of 38.5% to 50%. [19] [20] [21] One possible explanation for this is that gene copy number (GCN) may not lead to functional messenger RNA (mRNA) expression and therefore has limited value for predicting FGFR1 pathway addiction. In a cohort of 151 resected primary lung tumors comprising the entire spectrum of NSCLC histology, 6 (46%) of 13 samples with GCN ! 4 also had high mRNA expression (4þ, per RNA scope guidelines). Conversely, 6 (13.6%) of 44 samples with mRNA 4þ also had GCN ! 4. 22 Regarding the predictive potential of these biomarkers in 58 cell lines across different lung cancer histologies, including SQLC, adenocarcinoma, and SCLC, FGFR1 gene amplification, mRNA transcription, and protein expression were quantified before FGFR tyrosine kinase inhibitor therapy. After treatment with ponatinib, a multikinase inhibitor of FGFR1, -2, -3, and -4 (drug concentration causing 50% inhibition [IC 50 ] ¼ 2, 2, 18, and 8 nmol/L, respectively), 23 as well as platelet-derived growth factor receptors alpha and beta, rearranged during transfection (RET), and vascular endothelial growth factor receptors 1 to 3 (IC 50 0.2-8 nmol/L), these cell lines were ranked by their IC 50 for inhibiting proliferation. When ponatinib sensitivity was correlated with each cell line's corresponding FGFR1 mRNA, protein, and GCN score, FGFR1 mRNA (area under the curve [AUC] 0.905) and protein (AUC 0.887) were more predictive of ponatinib sensitivity compared to FGFR1 GCN (AUC 0.691). 22 On the basis of this preclinical data, a phase 2 trial was designed to determine the prevalence of and factors associated with FGFR 1 biomarker (GCN and mRNA) positivity in NSCLC and SCLC, and to explore the predictive value of these biomarkers for ponatinib sensitivity.
Patients and Methods

Prescreening for Ponatinib Biomarkers
Using formalin-fixed, paraffin-embedded (FFPE) cell line pellets, clinically translatable mRNA (in-situ hybridization, ISH) and GCN (silver in-situ hybridization, SISH) assays were developed as previously described. 22 FGFR1 immunohistochemistry applicable to the same tissues was not available when this protocol was designed. Unlike oncogenic point mutations or gene rearrangements, GCN, mRNA levels, and protein expression levels represent continuous variables. This cell line work was then utilized to predict initially clinically relevant cut points for FGFR1 inhibitor sensitivity using a ponatinib IC 50 50 nM based on the predicted serum trough level of 60 nM at the recommended phase 2 dose of 45 mg received orally daily in a previous clinical trial. 24 Patients ! 18 years of age with advanced lung cancer of all histologies (NSCLC and SCLC) other than carcinoid were prescreened for tumoral FGFR1 GCN by SISH and for FGFR1 mRNA levels by ISH. If the underlying histology was NSCLC with adenocarcinoma or not otherwise specified, the patient had to be negative for both EGFR mutations and ALK rearrangements. Lung cancer specimens with KRAS mutation were not excluded from prescreening because KRAS mutations were present in some FGFR1 positive cell lines that responded to ponatinib. 22 If sufficient tissue remained and the RET rearrangement status was not already known, patients with adenocarcinoma or not otherwise specified histologies testing negative for both FGFR1 ISH and SISH (and for the University of Colorado Hospital internal cases, who were also pan-negative for other known drivers) were then tested for RET rearrangement, a further known target of ponatinib, by FISH.
FGFR1 mRNA Testing by ISH
mRNA ISH was performed on FFPE tumor tissue samples using the RNA scope 2.0 assay system with recommended probes from Advanced Cell Diagnostics (FGFR1 Cat. 310071). ISH scores were generated and recorded using the following scoring system at 200Â magnification: 0, no staining; 1, 1 to 3 dots per tumor cell; 2, 4 to 10 dots per tumor cell; 3, more than 10 dots per cell or presence of dot clusters in ! 1% and < 10% tumor cells; and 4, ! 10% tumor cells with dot clusters as per the RNA scope system scoring guidelines. 18 The predefined cut point for FGFR1 ISH positivity was a score of 3 or 4 per this scoring system. FGFR1 SISH has been validated against FGFR1 FISH.
22
FGFR1 Gene Amplification by SISH 
Additional Molecular Testing
Hematoxylin and eosinestained, paraffin-embedded sections were examined by a board-certified anatomic pathologist for testing suitability. Tumor cells were isolated by microscope assisted microdissection followed by tumor cell lysis and DNA extraction.
Mutational analysis of EGFR, KRAS, BRAF, and ERBB2 (HER2) were carried out either by real-time PCR for individual targets (Qiagen) or TruSight Tumor sequencing panel (Illumina) for multiple gene targets.
Using a manual slide processing fluorescence in-situ hybridization (FISH) technique, paraffin sections were hybridized with fluorescent probes. MET probe (Vysis LSI MET SpectrumRed Probe) in combination with CEP7 probe (Vysis CEP7 SpectrumGreen Probe) was utilized to score for MET amplification. 26 The received FFPE specimen was subjected to the standard FISH laboratory protocol and hybridized with these probe sets. 27 Analyses were performed in fluorescence microscope with proper interference filters.
Study Design and Treatment
This was an open-label, phase 2, biomarker-driven study of ponatinib monotherapy divided into a prescreening phase and a treatment phase The study protocol was approved by the Colorado institutional review board, and the study was performed in accordance with the Declaration of Helsinki. Prescreened patients were categorized into 4 molecular cohorts on the basis of ISH and SISH positivity: The secondary objectives were to determine the clinical and pathologic features associated with biomarker positivity and negativity at the predefined cut point and at higher cut points (where applicable), to determine the safety, tolerability, and adverse event (AE) profile of ponatinib in patients with advanced lung cancer, to determine the progressionfree survival, pattern of failure (central nervous system vs. extraecentral nervous system) and response duration (in those who experienced objective response) of ponatinib in the molecularly defined cohorts, and to determine the ORR in RET þ NSCLC and in the FGFR1 double-negative cohort.
The study used a 1-stage design. 28 In each molecularly defined cohort, the study required 12 subjects to decide whether ORR is greater than 40%, assuming the response rate is 5%, without treatment. Twelve subjects per cohort provided over 90% power to detect this rate difference, with a targeted type I error rate of 0.05 and an actual error rate of 0.02. If the disease of ! 3 patients responded per molecular cohort, then the hypothesis that P .05 (null hypothesis) would be rejected, but if the disease of 2 patients responded, then the hypothesis that P ! .40 would be rejected.
Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. A dose level was considered tolerable after completion of 1 cycle (28 days) in 9 of 12 patients in the absence of dose-limiting toxicity. AEs were assessed at screening, on days 1, 8, and 15 of cycle 1, and day 1 of each further cycle in the first 12 patients accrued in the entire study. All other patients had AEs assessed at screening and on day 1 of each cycle. Disease was assessed by computed tomography or positron emission tomography/ computed tomography (including intravenous contrast if target lesions included those other than parenchymal lung lesions) with or without brain imaging, as indicated per protocol at baseline, and then every 2 cycles (8 weeks) per RECIST v1.1 by local investigators. Median overall survival (OS) was calculated by the Kaplan-Meier method.
Patients received ponatinib 45 mg received orally daily in the
Exposures at the standard ponatinib dose of 45 mg 4 times a day were predicted to be sufficient to affect FGFR1 in vivo. During the course of the trial, a black box warning (October 2013) emerged regarding the potential vascular complications associated with ponatinib use. A series of US Food and Drug Administrationemandated protocol changes were then introduced. Because of the potential for long-term vascular risks with ponatinib, doses above 45 mg 4 times a day were not explored. Subjects with a history of vascular complications were excluded. In the absence of contraindications, low-dose aspirin provided at 81 mg 4 times a day and a statin (eg, atorvastatin provided at 10 mg 4 times a day) were recommended to mitigate the risk of vascular complications. Because the IC 50 for RET is an order of magnitude lower than for
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Ponatinib Treatment Eligibility
Key inclusion criteria were as follows: all NSCLC and SCLC patients were eligible for prescreening, met biomarker criteria
using one of the assays described, had measurable disease per RECIST v1.1, had received prior platinum-based chemotherapy, had a life expectancy of ! 3 months, had Eastern Cooperative Oncology Group performance status 0 to 2, and had normal hematologic, renal, and hepatobiliary function. Patients with central nervous system metastases were eligible if they had stable central nervous system disease. Key exclusion criteria were as follows: history of clinically significant bleeding disorder, clotting disorder (myocardial infarction, stroke, venous/arterial thromboembolism), acute pancreatitis within 1 year of the study or history of chronic pancreatitis, uncontrolled hypertriglyceridemia (triglyceride > 450 mg/dL), and history of ventricular arrhythmia (except premature ventricular complexes).
Clinical and Molecular Correlation With Biomarker Positivity
Clinical and pathologic features were collected, including age at diagnosis of metastatic lung cancer, sex, histology, sites of metastatic disease at diagnosis, smoking status, other known molecular drivers including EGFR, KRAS, ALK, ROS1, BRAF V600, MET amplification, MET exon 14 skip lesion, HER2 mutation, HER2 amplification, response to first-line platinum doublet chemotherapy for metastatic lung cancer, and OS from the date of diagnosis of metastatic disease. Association of these features and treatment response to ponatinib with biomarker positivity at the predefined cut point, and at higher cut points (where applicable), were explored. In addition to the predefined 4 molecular cohorts (
and ISH were assessed separately to maximize the sample size if each molecular cohort was too small as a result of slow accrual. Descriptive information for the molecular subgroups for categorical variables were computed, and differences between the molecular cohorts were assessed by the Fisher exact test. For continuous variables, the differences between the molecular cohorts were assessed by the Kruskal-Wallis rank sum test because of their nonnormal distribution. Kaplan-Meier curves were used to examine OS (from metastatic diagnosis) between the molecular cohorts, and differences in survival times were assessed by the log-rank test. A significance level of .05 was used for all hypothesis testing, and P values were not corrected for multiple testing because of the exploratory nature of this work.
Results
In October 2013, after the black box warning regarding ponatinib-associated vascular issues, the treatment aspects of the protocol were put on hold, but prescreening continued. From September 2013 to November 2017, a total of 171 patient samples were prescreened by FGFR1 ISH and SISH. Forty (23.4%) had insufficient tissue or failed screening; 4 had incomplete clinical information. As a result, the data of 127 patients were analyzable. After protocol modifications were made, the treatment aspect of the protocol was reopened, but the awareness of the risks associated with ponatinib and the additional inclusion and exclusion criteria severely limited the number of cases eventually treated with the drug. 
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Exploration of Alternative FGFR1 Positivity Cut Points
When the results of all 123 SISH-tested patients were plotted in a continuum from lowest to highest score, the data suggested that the preexisting definition for SISH positivity, FGFR1/CEP8 ! 2.0, and/or FGFR1 mean GCN ! 4 was appropriate because this cut point best demarcated the greatest change in the slope of the curve (Supplemental Figure 1 in the online version) . Furthermore, there were only 9 SISH þ patients at the current cut point. A higher SISH cut point would further reduce the number of SISH þ patients, limiting the ability to detect group differences.
To determine if an alternative FGFR1 ISH positive cut point should be considered, results of all 126 ISH-tested patients were Abbreviations: FGFR ¼ fibroblast growth factor receptor; ISH ¼ in-situ hybridization; SISH ¼ silver in-situ hybridization. plotted in a continuum from lowest to highest score. ISH ! 20% tumor cells with dot clusters was selected as an alternative cut point for positivity because this metric clearly separated those with high ISH scores from those with a negative or low-positive ISH scores ( Figure 4 ). Using this new cut point, the data of all 126 patients with reported ISH scores were then explored to see if the new cut point was associated with distinguishing clinical and molecular features as a means of suggesting that patients with ISH scores above this cut point represented a biologically distinct subset than those below it. Clinical and molecular characteristics associated with the ISH ! 20% (n ¼ 29) and ISH < 20% (n ¼ 97) subgroups are summarized in Table 3 . Two of the 4 patients with a best response of stable disease from ponatinib were ISH ! 20%, whereas the 2 ponatinibtreated patients with a best response of PD were ISH < 20%. Of the 126 patients tested for ISH, 29 patients (23.0%) were ISH ! 20%. In the ISH ! 20% group, more patients had soft tissue metastases (17.2% vs. 5.0%, P ¼ .050) and small-cell histology (34.5% vs. 11.3%), whereas fewer patients had adenocarcinoma (51.7% vs. 71.1%) and squamous carcinoma (13.8% vs. 17.5%) (P ¼ .022). Using the new cut point, survival continued to be significantly shorter in the ISH ! 20% group (median OS, 394 days [95% CI: 318-NA] vs. 730 days [95% CI: 548-1046], P ¼ .031) (Supplemental Figure 2 in the online version). The prevalence of concomitant KRAS mutation in both ISH ! 20% and ISH < 20% was high (45.0% vs. 47.6%, respectively; P ¼ 1.00).
Discussion
Recent efforts have explored FGFR1 gene amplification, as defined by either an increased GCN (! 4) or an FGFR1/CEP8 ratio ! 2.0, in squamous lung cancer as a predictive biomarker for response to FGFR1 inhibitors, including AZD4547, BGJ398, and dovitinib, with modest success. [19] [20] [21] The response rate to these agents ranges 8% to 11.5%. In this study, ponatinib, a pan-FGFR inhibitor that was originally developed for treatment-refractory chronic myelogenous leukemia, was used in this FGFR1 biomarkeredriven study, partly to test the efficacy of ponatinib in FGFR1-positive patients compared to FGFR1-negative patients, given the rationale that FGFR1 positivity would more likely identify lung cancers in an FGFR1-addicted state. As demonstrated in our study and in other preclinical and clinical studies, FGFR1 ISH and SISH only partially overlap, suggesting that FGFR1 gene amplification does not always lead to downstream transcription, and also that elevated transcription can occur in the absence of gene amplification. 20, 22 All of this evidence strongly suggests that FGFR1 gene amplification is insufficient as a predictive biomarker when used in isolation. This study is an early effort to explore the feasibility of using novel biomarkers instead of or in addition to FGFR1 gene amplification to predict response to FGFR1 inhibitors such as ponatinib.
Initial ISH positivity was defined as presence of dot clusters (! 1% of tumor cells) or > 10 dots per cell in ! 10% tumor cells. Initial SISH positivity was defined as average of at least 4 FGFR1 signals per nucleus (GCN) or FGFR1/CEN8 ratio ! 2.0. Using these criteria, 7.3% patients were SISH þ and 42.1% were ISH þ . At the initial ISH and SISH cut points, no specific correlation with age, sex, smoking status, or response to platinum therapy were identified. SISH-positive disease was less likely to harbor a coincident KRAS mutation than SISH-negative disease, and ISH-positive cases had worse OS than ISH-negative cases. Exploration of the spread of (Figure 4 ). The objective of exploring FGFR1 ISH at a higher cut point was to see whether a subset of patients with much higher mRNA expression would reveal a biologically distinct subset of patients that is based on significant differences in clinical and molecular features. Using this higher cut point, FGFR1 ISH positivity was associated with SCLC histology and soft tissue metastases at diagnosis, and remained associated with shorter OS in univariate analysis. Given the small number of patients with small-cell and squamous histology, multivariable analysis to control for variables that showed a significant association with FGFR1 positivity in univariate analysis was not feasible.
Unfortunately, as a result of poor tolerability and safety concerns regarding ponatinib after treating the first few patients, the study did not reach its accrual target (n w 70) for the treatment portion of this study, so we could not confirm or refute the null hypothesis, as we needed a minimum of 12 patients treated. This study prescreened a more heterogeneous population, including lung adenocarcinoma, which is amenable to a much larger arsenal of treatment options than squamous lung cancer, and SCLC, which, because of its rapidly progressive nature, often precludes patients from receiving the drug after initial lines of chemotherapy. As a result, all 4 patients who were enrolled onto the ponatinib treatment arm had either squamous or poorly differentiated lung cancer.
Because the number of patients treated with ponatinib was small (n ¼ 4), the ability to deduce the value of these FGFR1 biomarkers for predicting benefit from this drug was limited. Although the 4 FGFR1 preselected patients treated with ponatinib had a response rate of 0, half of them still had a best response of stable disease.
The apparent lack of response to ponatinib in a FGFR1-preselected population could be due to multiple factors. The disease of the treated patients may not have responded because ponatinib was not potent enough to inhibit FGFR1 signaling, and the maximum tolerated dose was limited because of its many off-target effects. Our data suggest that FGFR1 biomarker positivity, especially at higher cut points, may enrich for a biologically distinct subset that may be dependent on FGFR1 activation and signaling, which in turn may predict sensitivity to FGFR1 inhibitors such as ponatinib. However, FGFR1 gene amplification and mRNA expression by SISH and ISH may not be the best biomarker to determine FGFR1 addiction, considering FGFR1 signaling may be dependent on autocrine and paracrine ligand binding, 22, 30 FGFR1 gene amplification and mRNA expression may not lead to functional activation, FGFR1 expression is likely heterogeneous within and between tumors, 20 and neither gene amplification nor mRNA overexpression necessarily determines a state of constitutive activation of cell proliferation, differentiation, and survival, unlike gain-of-function mutations such as EGFR-activating mutation or KRAS mutation. Finally, a true FGFR1-addicted state may be so rare that the cut point of ISH and SISH needed to be so much higher that our relatively small sample size of prescreened patients was insufficient to differentiate those patients. This sample of 127 patients with analyzable data provides a rich data set for biomarker exploration. That FGFR1 mRNA (ISH) did not seem to be very specific for an oncogene-addicted state may reflect a less robust methodology of scoring compared to FGFR1 SISH. Whereas SISH requires the pathologist to average the number of cell signals per nucleus over 50 cells, ISH criteria does not mandate a minimum number of cells examined. Instead, the pathologist scores the tissue sample on the basis of a global impression and provides a best estimate of the number of dots per cell and the percentage of tumor cells with dot clusters. That these 2 biomarkers are not completely overlapping suggests that neither biomarker is sufficient as a stand-alone biomarker. Other than suboptimal patient enrollment, another limitation is that a FGFR1 antibody to detect FGFR1 protein expression by immunohistochemistry was not implemented into the biomarker, set no validated antibody was available at the time.
Conclusion
High FGFR1 mRNA expression is more common than FGFR1-AMP and was associated with worse OS. Higher levels of FGFR1 mRNA expression and gene amplification may be associated with a specific phenotype and is worthy of further exploration. Ponatinib's poor tolerance suggests further FGFR exploration in ISH þ cases should utilize more selective FGFR1 inhibitors.
Clinical Practice Points
Recent trials of FGFR1 inhibitors in SQLC with FGFR1 gene amplification showed modest response rates. Preclinical experiments on NSCLC and SCLC cancer cell lines and resected tumors demonstrated that FGFR1 mRNA and protein overexpression were more predictive of ponatinib sensitivity than FGFR1 gene amplification.
On the basis of these data, a phase 2 biomarker-driven study using FGFR1 gene amplification by SISH and mRNA expression by ISH in NSCLC and SCLC patients treated with ponatinib was conducted. A total of 171 patient samples were prescreened using FGFR1 ISH and SISH, and 127 cases were analyzable. The prevalence of FGFR1 ISH þ and SISH þ cases was 42.1% and 7.3%, respectively. Because of a black box warning regarding potential vascular complications associated with ponatinib, the drug was put on hold. Although the treatment aspect of the protocol was reopened after protocol modification, as a result of awareness of ponatinib-associated risks, only 4 patients were treated with ponatinib 45 mg provided orally daily. The ORR was 0 with a disease control rate of 50% (stable disease in 2 patients with a high FGFR1 ISH score).
Association of clinicopathologic features with FGFR1 ISH and SISH positivity at different cut points were explored. FGFR1 ISH positivity at a higher cut point may identify a distinct clinical phenotype (soft tissue metastases, small-cell histology, worse survival) of lung cancer patients who may benefit from FGFR1 inhibition and is worthy of further exploration. Ponatinib's poor tolerance suggests further FGFR exploration in ISH þ cases should utilize more selective FGFR1 inhibitors.
